Spantide I TFA, a selective NK1 receptor antagonist and a substance P analog, exhibits K(i) values of 230 nM for NK1 and 8150 nM for NK2 receptors, respectively. It offers a method to decrease type 1 while increasing type 2 cytokine IL-10 in the infected cornea, significantly reducing corneal perforation [1] [2] [3].